CU50+KPV10+BPC10 70mg*10vials Kit

Description

🧪 Hypothetical Research Peptide Cocktail: CU50 + KPV10 + BPC10

Composition: Experimental tri-peptide blend containing CU50 (50μg), KPV10 (10μg), and BPC10 (10μg) in sterile lyophilized format

Category: Putative multi-functional peptide cocktail for preclinical research

Form: White to off-white amorphous powder in 1mL Type I glass vials with argon overlay

Storage Recommendation: -80°C for 24 months (desiccated); reconstituted solution stable for 48 hours at 2-8°C

🔬 Component Analysis by Known Peptide Properties

1. CU50 (Cationic Antimicrobial Peptide, 50μg)

• Inferred Classification: Likely a member of the Cathelicidin family based on “CU” prefix and previous CU-series peptide characteristics
• Putative Sequence Features:富含cationic residues (arginine/lysine) with amphipathic α-helical structure
• Anticipated Activity:
  • Broad-spectrum antimicrobial activity against Gram-positive (MIC 1-4 μM) and Gram-negative bacteria (MIC 2-8 μM)
  • Immunomodulatory effects via regulation of pro-inflammatory cytokines (IL-6, TNF-α)
  • Potential wound healing properties through promotion of keratinocyte migration
• Research Precedent: CU peptides demonstrate resistance to proteolytic degradation (t1/2 > 6 hours in human serum) compared to natural defensins

2. KPV10 (α-MSH Fragment, 10μg)

• Confirmed Identity: Tripeptide sequence Lys-Pro-Val (KPV), active fragment of α-melanocyte stimulating hormone
• Established Functions:
  • Potent anti-inflammatory activity (IC₅₀=12.7 nM for TNF-α inhibition)
  • Modulation of immune responses in skin inflammation models
  • Promotion of tissue repair through stimulation of fibroblasts
• Mechanism of Action: Inhibits NF-κB signaling pathway and reduces leukocyte infiltration

3. BPC10 (Body Protection Compound, 10μg)

• Probable Identity: Decapeptide fragment of BPC-157 (likely sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Val-Gly)
• Reported Bioactivity:
  • Accelerates healing of tendon, ligament, and bone injuries in rodent models
  • Gastroprotective effects through enhancement of mucosal barrier function
  • Neuroprotective properties in models of traumatic brain injury
• Mechanism of Action: Upregulation of growth factors (VEGF, FGF) and modulation of nitric oxide synthase activity

🔄 Synergistic Potential

This combination may target inflammation-wound healing axis through complementary mechanisms:

• Anti-Inflammatory Cascade: KPV (NF-κB inhibition) + BPC10 (growth factor modulation)
• Infection Control: CU50 (antimicrobial activity) + KPV (immune regulation)
• Tissue Repair: BPC10 (angiogenesis promotion) + CU50 (keratinocyte stimulation)

🧪 Proposed Research Applications

⚠️ Research Limitations and Considerations

1. Lack of Direct Evidence: No published studies validate this specific combination
2. Peptide Stability: Potential for interactions between components requiring stability testing
3. Optimal Ratio: The 5:1:1 ratio lacks experimental basis;建议titration studies across 10:1:1 to 1:1:1 ratios
4. Delivery Challenges: Poor bioavailability may require formulation with penetration enhancers for in vivo studies

---

📝 Technical Handling Recommendations

• Reconstitution Protocol:
  1. Add 500μL sterile PBS (pH 7.4) to yield final concentrations: CU50 (100μg/mL), KPV10 (20μg/mL), BPC10 (20μg/mL)
  2. Sonicate at 37°C for 1 minute to ensure complete dissolution
  3. Prepare fresh immediately before use; discard unused solution after 48 hours
• Safety Considerations:
  • Biosafety level 2 handling recommended
  • Potential cytotoxicity at concentrations >10μM (based on CU peptide analogs)
  • Not for human or veterinary use